Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06017583 |
Recruitment Status :
Recruiting
First Posted : August 30, 2023
Last Update Posted : October 11, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Rectal Neoplasms | Drug: Tislelizumab Drug: Capecitabine Drug: Oxaliplatin Radiation: SIB-IMRT Radiation: IMRT | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 48 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | The random number table method. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With Simultaneous Integrated Boost Intensity-modulated Radiotherapy in the Treatment of Locally Advanced Rectal Cancer |
Actual Study Start Date : | September 1, 2023 |
Estimated Primary Completion Date : | August 31, 2024 |
Estimated Study Completion Date : | August 31, 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: Experimental arm
The experimental group will receive concurrent simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) and concurrent capecitabine chemotherapy, and complete 2 ~ 4 cycles of XELOX chemotherapy, while receiving full tislelizumab treatment for at least 4 cycles (21 days per cycle).
|
Drug: Tislelizumab
Tirellizumab was administered intravenously at 200mg/d1, 21 days per cycle, with at least 4 cycles completed. Drug: Capecitabine Oral capecitabine 825mg/m2 bid, radiotherapy day concurrent chemotherapy. Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed. Drug: Oxaliplatin Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed. Radiation: SIB-IMRT The tumor and the related mesenteric region 1cm above and below were simultaneously integrated boost to 5600cGy with the intensity-modulated radiotherapy. The other dose for clinical target volume is 5000 cGy. |
Placebo Comparator: Control arm
The control group received intensity-modulated radiotherapy (IMRT) without tirellizumab, and the other treatment regiments were consistent with the experimental group.
|
Drug: Capecitabine
Oral capecitabine 825mg/m2 bid, radiotherapy day concurrent chemotherapy. Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed. Drug: Oxaliplatin Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed. Radiation: IMRT The whole dose of the clinical target volume is 5000 cGy with intensity-modulated radiotherapy. |
- Complete response rate [ Time Frame: 12 weeks~18 weeks ]Include in pathological complete response rate and clinical complete response rate. MRI/CT will be used for evaluating the carcinoma status. Pathological complete response rate will be evaluated by surgery.
- Side effects [ Time Frame: 6monthes, 3years ]Myelosuppression, radiation enteritis, radiothermitis
- Overall survival [ Time Frame: 3 years ]OS was calculated from the date of entry into the study to the date of death or the last follow-up visit.
- Disease free survival [ Time Frame: 3 years ]DFS was calculated from the date of entry into the study to the date of the time from the beginning of randomization to the disease recurrence or progression or death from any cause.
![](/ct2/html/images/NIH_NLM_ABRV_BLK_4.png)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Aged 18 to 70 years.
- The pathological type of rectal cancer diagnosed by histopathology is adenocarcinoma.
- Patients with T3-4 in the eighth AJCC stage or positive regional lymph node and no distant metastasis.
- Having at least one measurable lesion according to RECIST 1.1.
- ECOG score 0-1.
- Expected survival time ≥6 months.
- Major organ function is normal, that is, meeting the following criteria: blood routine: HB≥90g/L, ANC≥1.5×109/L, PLT≥80×109/L; Biochemical examination of ALB≥30g/L, TBIL≤1.5 ULN, ALT and AST≤2.5 ULN, plasma Cr≤1.5 ULN or creatinine clearance ≥60 ml/min.
- Subjects volunteered to join the study, signed the informed consent, had good compliance, and cooperated with follow-up.
Exclusion Criteria:
- Patients have had or currently have other malignant tumors within 5 years.
- Patients allergic or sensitive to any drug in the study protocol.
- Patients innate or acquired immune deficiency (e.g. HIV infection).
- The presence of any active, known or suspected autoimmune disease (such as, but not limited to, interstitial pneumonia, uveitis, enteritis, hepatitis, arthritis, nephritis, hypophysitis, hyperthyroidism, hypothyroidism, etc.); The subject had vitiligo. Subjects with asthma require bronchodilators for medical intervention.
- The presence of active infections requiring systemic treatment.
- The subject has previously received other PD-1 or PD-L1, or CTLA-4 antibody therapy, or other drug therapy targeting immunoregulatory receptor preparations.
- Unrelieved toxic effects above CTCAE grade 1 due to any previous treatment, excluding alopecia.
- Patients with a history of myocardial infarction or stroke, unstable angina pectoris, decompensated heart failure or deep vein thrombosis.
- Patients with long-term untreated wounds or fractures, major surgical operations or severe traumatic injuries, fractures or ulcers within 4 weeks.
- Pregnant or lactating women.
- Patients with liver and kidney dysfunction.
- Patients with a history of abuse of psychotropic drugs and unable to abstain or patients with mental disorders.
- Patients who have participated in clinical trials of other drugs within 4 weeks.
- Patients with concomitant diseases that, in the judgment of the investigator, seriously endanger the patient's safety or affect the patient's completion of the study.
- The investigator judged that participation in this study was not conducive to the maximum benefit of the subjects.
![](/ct2/html/images/NIH_NLM_ABRV_BLK_4.png)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06017583
China, Guangxi | |
First Affiliated Hospital of Guangxi Medical University | Recruiting |
Nanning, Guangxi, China, 530021 | |
Contact: Yong Zhang, PhD 13607884001 zhangyonggx@163.com | |
Contact: Shanshan Ma, PhD 13557994302 mashanshan@gxmu.edu.cn |
Responsible Party: | Yong Zhang,MD, First Affiliated Hospital of Guangxi Medical University |
ClinicalTrials.gov Identifier: | NCT06017583 |
Other Study ID Numbers: |
2023-S845-01 |
First Posted: | August 30, 2023 Key Record Dates |
Last Update Posted: | October 11, 2023 |
Last Verified: | October 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Rectal cancer Tislelizumab SIB IMRT |
Rectal Neoplasms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases |
Rectal Diseases Capecitabine Oxaliplatin Tislelizumab Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Antineoplastic Agents, Immunological |